Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.57 |
| ▸ | ACE | P12821 | 4/20 | 0.57 |
| ▸ | CPA1 | P15085 | 2/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 2/20 | 0.51 |
| ▸ | MC5R | P33032 | 2/20 | 0.51 |
| ▸ | MC3R | P41968 | 2/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30643724 | 0.91 | ERAP2 (0.55) | MMEACECPA1ACE2CA2 | |
| SCHEMBL30973666 | 0.91 | ERAP2 (0.55) | MMEACECPA1ACE2CA2 | |
| SCHEMBL31167405 | 0.90 | MME (0.50) | MMEACECPA1ACE2MC4R | |
| SCHEMBL31253365 | 0.89 | ERAP2 (0.53) | MMEACECPA1ACE2MC4R | |
| SCHEMBL31026925 | 0.89 | MME (0.65) | MMEACECPA1ACE2CA2 | |
| SCHEMBL12464463 | 0.87 | FCER2 (0.52) | FCER2 | |
| SCHEMBL31264142 | 0.87 | MME (0.66) | MMEACECPA1ACE2CA2 | |
| SCHEMBL29494074 | 0.87 | MME (0.66) | MMEACECPA1ACE2CA2 | |
| SCHEMBL1374146 | 0.87 | MMP2 (0.64) | MMEACECPA1ACE2ITGB3 | |
| SCHEMBL1374145 | 0.87 | MMP2 (0.64) | MMEACECPA1ACE2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612343-B2 | PSMA binder and use thereof | Shiya Pharmaceutical, Inc (CN) | 2026-04-28 | — | — | US | disclosed |
| US-20250360236-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-11-27 | — | — | US | disclosed |
| EP-4525935-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Deutsches Krebsforschungszentrum (DE) | 2025-03-26 | — | — | EP | disclosed |
| CN-119156234-A | Prostate Specific Membrane Antigen (PSMA) ligands | 德国癌症研究中心公共法律基金会 | 2024-12-17 | — | — | CN | disclosed |
| WO-2023222679-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023222682-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2023-11-23 | — | — | WO | disclosed |
| US-11638765-B2 | Double-labeled probe for molecular imaging and use thereof | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-05-02 | — | — | US | disclosed |
| US-20220315507-A1 | PSMA BINDER AND USE THEREOF | SHANGHAI FO ZE MEDICAL TECHNOLOGY CO., LTD (CN) | 2022-10-06 | — | — | US | disclosed |
| EP-4011903-A1 | PSMA COMBINER AND USE THEREOF | Shanghai Fo Ze Medical Technology Co., Ltd. (CN) | 2022-06-15 | — | — | EP | disclosed |
| US-20220118121-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS WITH IMPROVED TISSUE SPECIFICITY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360236-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | KLK3, FOLH1, MPI | MME 381/4885ACE 2427/4885CPA1 303/4885 |
| US-20220315507-A1 | PSMA BINDER AND USE THEREOF | KLK3, FOLH1, SHBG | MME 431/4885ACE 3174/4885CPA1 774/4885 |
| US-12612343-B2 | PSMA binder and use thereof | KLK3, AR, PSMA1 | MME 981/4885ACE 1449/4885CPA1 48/4885 |
| US-11638765-B2 | Double-labeled probe for molecular imaging and use thereof | ANXA1, ANXA5, CD47 | MME 3220/4885ACE 4306/4885CPA1 983/4885 |
| US-20220118121-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS WITH IMPROVED TISSUE SPECIFICITY | FOLH1, ACP3, PSMA3 | MME 859/4885ACE 3632/4885CPA1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.